Determination of amphetamine, methamphetamine, and hydroxyamphetamine derivatives in urine by gas chromatography-mass spectrometry and its relation to CYP2D6 phenotype of drug users

Journal of Analytical Toxicology

Volumn 31, Issue 1, 2007, Pages 31-36

  Miranda G , Elias ^a,b   Sordo, Monserrat ^a   Salazar, Ana M ^a   Contreras, Claudia ^b   Bautista, Leoncio ^b   Rojas García, Aurora E ^c   Ostrosky Wegman, Patricia ^a,d  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b SCT   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE NAYARIT   (Mexico)

^d INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; CYTOCHROME P450 2D6; HYDROXYAMPHETAMINE; METHAMPHETAMINE;

ARTICLE; CALIBRATION; CORRELATION ANALYSIS; DRIVING ABILITY; DRUG ABUSE; DRUG DEPENDENCE; DRUG DETERMINATION; DRUG METABOLISM; DRUG URINE LEVEL; DRUG USE; GAS CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PARKINSON DISEASE; PHENOTYPE; REPRODUCIBILITY; RISK ASSESSMENT; URINALYSIS; VALIDATION PROCESS;

EID: 33847736992     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/31.1.31     Document Type: Article

References (31)

1. M.Y. Law, M.H. Slawson, and D.E. Moody. Selective involvement of P450 2D subfamily in vivo 4-hidroxylation of amphetamine in rat. Drug Metab. Dispos. 28: 348-353 (2000).
2. M.J. De Groot, G.J. Bijloo, B.J. Martens, F.A. Van Acker, and N.P. Vermeulen. A refined substrate model for human. Chem. Res. Toxicol. 10: 41-48 (1997).
3. D. Wu, S.V. Otton, T. Inaba, W. Kalow, and E.M. Sellers. Interactions of amphetamine analogs with human liver CYP2D6. Biochem. Pharmacol. 53: 1605-1612 (1997).
4. L.Y. Lin, E.W. Distefano, D.A. Schmitz, L. Hsu, S.W. Ellis, M.S. Lennard, G.T. Tucker, and A.K. Cho. Oxidation of methaphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab. Dispos. 25: 1059-1064 (1997).
5. S. Mc-Elroy, J. Richmond, M. Lira, D. Friedman, B.M. Silber, and P.M. Milos. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS Pharmsci. 2: 1-11 (2000).
6. M. Ingelman-Sundberg. The human genome project and novel aspects of P450 research. Toxicol. Appl. Pharmacol. 207: 52-56 (2005).
7. F.J. Gonzalez, R.C. Skoda, S. Kimura, M. Umeno, U.M. Zanger, D.W. Nebert, H.V. Gelboin, J.P. Hardwick, and U.A. Meyer. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442-446 (1988).
8. L.G. Dring, R.L. Smith, and R.T. Williams. The metabolic fate of amphetamine in man and other species. Biochem. J. 116: 425-435 (1970).
9. R.L. Smith. Human genetic variations in oxidative drug metabolism. Xenobiotica 16: 361-365 (1986).
10. C. Sachse, J. Brockmoller, S. Bauer, and I. Roots. P450 2D6 variants in a caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60: 284-295 (1997).
11. O. Tribut, Y. Lessard, J.M. Reymann, H. Allain, and D. Bentue-Ferrer. Pharmacogenomics. Med. Sci. Monit. 8: RA152-RA163 (2002).
12. I. Johansson, E. Lundqvist, L. Bertilsson, M.L. Dahl, F. Sjoqvist, and M. Ingelman-Sundberg. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Nat. Acad. Sci. 90: 11825-11829 (1993).
13. W. Chou, F. Yan, D.K. Robbins-Weilert, T.B. Ryder, W. Liu, C. Perbost, M. Fairchild, J. Leon, W.H. Koch, and P.J. Wedlund. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin. Chem. 49: 542-551 (2003).
14. R. Yuan, S. Madani, X. Wei, K. Reynolds, and S. Huang. Evaluation of P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 30: 1311-1319 (2002).
15. B. Greenhill, S. Valtier, and J.T. Cody. Metabolic profile of amphetamine and methamphetamine following administration of the drug famprofazone. J. Anal. Toxicol. 27: 479-484 (2003).
16. F.T. Peters, N. Samyn, M. Wahl, T. Kraemer, G.D. Boeck, and H.H. Maurer. Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. J. Anal. Toxicol. 27: 552-559 (2003).
17. N. Raikos, K. Christopoulou, G. Theodoris, H. Tsoukali, and D. Psaroulis. Determination of amphetamines in human urine by headspace solid-phase microextraction and gas chromatography. J. Chromatogr. B 789: 59-63 (2003).
18. A. Poklis, J. Still, P.W. Slattum, L.F. Edinboro, J.J. Saady, and A. Constantino. Urinary excretion of D-amphetamine following oral doses in humans: implications for urine drug testing. J. Anal. Toxicol. 22: 481-487 (1998).
19. S. Cheung, H. Nolte, S.V. Otton, R.F. Tyndale, P.H. Wu, and E.M. Sellers. Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. J. Chromatogr. B 690: 77-87 (1997).
20. M. Nishida, A. Namera, M. Yashiki, M. Yashiki, and T. Kojima, Routine analysis of amphetamine and methamphetamine in biological materials by gas chromatography-mass spectometry and on-column derivatization. J. Chromatogr. B 789: 65-71 (2003).
21. J.C. Miller and J.N. Miller. Statistics for Analytical Chemistry, E. Horwood, Ed. Ellis Horwood, London, U.K., 1998, pp 58-60.
22. L. Jih-Heng, H. Heng-Cheng, C. Wei-Bang, and L. Shih-Ku. Genetic toxicity of methamphetamine in vitro and in human abusers. Environ. Mol. Mutagen. 42: 233-242 (2003).
23. S. Gentili, M. Corneta, and T. Macchia. Rapid screening procedure based on headspace solid-phase microextraction and gas chromatography-mass spectrometry for the detection of many recreational drugs in hair. J. Chromatogr. B 801: 289-296 (2004).
24. L. Bertilsson, Y.Q. Lou, and Y.L. Du. Pronounced differences between native chinese and swedish populations in the polymorphic hydroxylations of debrisoquin and s-mephenytoin. Clin. Pharmacol. Ther. 51: 388-397 (1992).
25. U.A. Meyer. Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc. Natl. Acad. Sci. U.S.A. 91: 1983-1984 (1994).
26. A.E. Balant-Gorgia, L.P. Balant, and G. Ganone. High blood concentration of imipramine or clomipramine and therapeutic failure. Ther. Drug Monit. 11: 415-420 (1989).
27. U.A. Meyer. Pharmacogenetics and adverse drug reactions. Lancet 356: 1667-1671 (2000).
28. O. Santt, H. Baranova, E. Albuisson, Y.J. Bignon, and G. Lucotte. Interaction between GSTM1-null and CYP2D6-deficient alleles in the patogénesis of parkinson's disease. Eur. J. Neurol. 11: 247-251 (2004).
29. C.A. Smith, C.R. Wolf, A.C. Gough, N.K. Spurr, P.N. Leigh, B.A. Summers, A.E. Harding, D.M. Marangore, S.G. Sturman, A.C. Williams, and A.H. Schapira. Debrisoquine hydroxylase gene polymorphism and susceptibility to parkinsońs disease. Lancet 339: 1375-1377 (1992).
30. M. Armstrong and A.K. Daly. Mutant debrisoquine hydroxylation genes in parkinsońs disease. Lancet 339: 1017-1018 (1992).
31. J.A. Agundez, L. Gallardo, M.V. Ledesma, L. Lozano, A. Rodríguez-Lescure, J.C. Pontes, M.C. Iglesias-Moreno, J. Poch, J.M. Ladero, and J. Benitez. Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology 61: 59-63 (2001).